
Day One Biopharmaceuticals, Inc.
NASDAQ:DAWN
6.95 (USD) • At close June 5, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Day One Biopharmaceuticals, Inc. |
Symbool | DAWN |
Munteenheid | USD |
Prijs | 6.95 |
Beurswaarde | 704,465,900 |
Dividendpercentage | 0% |
52-weken bereik | 6.08 - 16.76 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jeremy Bender M.B.A., Ph.D. |
Website | https://dayonebio.com |
An error occurred while fetching data.
Over Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)